Symmetry Technologies Inc. licenses a Human Rejuvenation Nutraceutical product from an FDA compliant laboratory. It will sell under the name "Resurgencell" in the yearly $200 billion USD Nutraceutical market

Houston,Tx, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Symmetry Technologies Inc. (OTC:SMMR) is pleased to announce that it has licensed a Human Rejuvenation Nutraceutical product for retail sale from a US based FDA compliant laboratory that it will sell under the brand name "Resurgencell".

"Resurgencell" is Symmetry's initial entrant into the colossal Nutraceutical market which by the year 2015 is estimated have an estimated yearly global sales in excess of $200 Billion USD per year. The Company has received its first shipment of the "Resurgencell" product and is in the beginning stages of developing a website in order to sell the product. Symmetry Technologies Inc. has been exploring various avenues for a substantial online presence that will help promote the company and its products as well as direct customers and potential customers to the company online.

"We are focusing on an internet website to be live and active within the next 2-3 months. One that will not only promote the growth of the company and establish our brand but one that will also provide a potential revenue stream with online purchases," says President Chad Reed. "We are obviously excited about the possibilities of having an online presence that we can build upon. In conjunction with our retail launch, this could be a huge factor in future sales of our product"

About The Company:

The Company is in the business of creating, licensing and marketing nutraceutical products and is developing a proprietary human rejuvenation nutriceutical with the help of a small group of PhD molecular biologists. Symmetry believes that by isolating certain compounds, the effects will be inducement of apoptosis in senescent cells, stimulation of stem cell growth, and the suppression of herpes activity. The Company believes that by clearing tissues with short average telomere length and stimulating longer telomere cell growth, including differentiation from stem cell populations, while ameliorating the effects of HSV activity, they will produce an effect that is tantamount to cell rejuvenation. The Company is accomplishing these biological tasks using compounds that have been accepted as safe for human consumption and already approved by the FDA (Food and Drug Administration) for human use. Industry trends have shown that valid opportunities exist in the internet sales of nutraceuticals, This is based on the Company's belief that with effective marketing, astronomical opportunities will continue to exist in internet sales of both pharmaceutical and nutraceutical products, and that this multibillion dollar industry will continue to shift towards the majority of its sales being executed online. Additional information on the Company can be found at

Safe Harbor Statement:

This press release may contain forward-looking statements, within the meaning of Section 27 A of the 'Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. These forward-looking statements are only made as of the date of the press release and Symmetry Technologies Inc. does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

CONTACT: Chad Reed- President Source:Symmetry Technologies Inc.